IFIH1 and clinically amyopathic dermatomyositis: The phenotype of CADM defined initially as cutaneous manifestations of DM in absence of myositis2 subsequently came to be associated with RPILD and presence of anti-MDA5 in serum of these patients.3 However in our cohort of anti-MDA5 DM we report a prevalence of 44% for myositis, very early after the first symptom of the disease which is almost similar to the reported prevalence of 56% from another Indian cohort of MDA5 DM.6